Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

Aims To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes. Methods This dose‐ranging, double‐blind, placebo‐controlled trial randomized 495 participants with type 2 diabetes inadequately control...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2013-12, Vol.15 (12), p.1154-1160
Hauptverfasser:	Rosenstock, J., Seman, L. J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	add-on therapy Adverse events Analysis of Variance Antidiabetics Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - adverse effects blood pressure Blood Pressure - drug effects Body weight Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Drug Therapy, Combination empagliflozin Fasting Female Glucose Glucosides - administration & dosage Glucosides - adverse effects Glycated Hemoglobin A - metabolism HbA1c Hematocrit - methods Hemoglobin Humans Hyperglycemia Hyperglycemia - drug therapy Hypoglycemia Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Infections Male Metformin Metformin - administration & dosage Metformin - adverse effects Middle Aged Placebos SGLT2 inhibitor Sodium-glucose cotransporter Sodium-Glucose Transporter 2 - antagonists & inhibitors tolerability Treatment Outcome Urinary tract
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!